News coverage about Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) has trended somewhat positive recently, according to Accern. Accern rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neovasc Inc (US) earned a news impact score of 0.16 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 46.3007843067043 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- Luminex (LMNX) and Neovasc Inc (US) (NVCN) Head-To-Head Review (americanbankingnews.com)
- Critical Analysis: Neovasc Inc (US) (NVCN) and The Competition (americanbankingnews.com)
- Head to Head Analysis: Neovasc Inc (US) (NVCN) & Its Rivals (americanbankingnews.com)
- Neovasc Inc. (NASDAQ: NVCN) – Is The Stock A Good Investment? – Alpha Beta Stock (alphabetastock.com)
- Financial Review: Neovasc Inc (US) (NVCN) vs. Its Competitors (americanbankingnews.com)
A number of equities research analysts have recently weighed in on the stock. ValuEngine downgraded shares of Neovasc Inc (US) from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Zacks Investment Research downgraded shares of Neovasc Inc (US) from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Neovasc Inc (US) has an average rating of “Hold” and a consensus price target of $5.19.
Neovasc Inc (US) Company Profile
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with MarketBeat.com's FREE daily email newsletter.